Compendium of Cancer Genome Aberrations

BRST5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(17 intermediate revisions by 3 users not shown)
Line 40: Line 40:
----
----
|-
|-
|Usual ductal hyperplasia
|[[BRST5:Usual ductal hyperplasia|Usual ductal hyperplasia]]
|Disease
|Disease
|
|
Line 51: Line 51:
|
|
|-
|-
|Columnar cell lesions, including flat epithelial atypia||Disease||
|[[BRST5:Columnar cell lesions, including flat epithelial atypia|Columnar cell lesions, including flat epithelial atypia]]||Disease||
|
|
|
|
Line 60: Line 60:
|
|
|-
|-
|Atypical ductal hyperplasia||Disease||
|[[BRST5:Atypical ductal hyperplasia|Atypical ductal hyperplasia]]||Disease||
|
|
|
|
Line 69: Line 69:
|
|
|-
|-
|Sclerosing adenosis||Disease||
|[[BRST5:Sclerosing adenosis|Sclerosing adenosis]]||Disease||
|
|
|
|
Line 78: Line 78:
|
|
|-
|-
|Apocrine adenosis and adenoma||Disease||
|[[BRST5:Apocrine adenosis and adenoma|Apocrine adenosis and adenoma]]||Disease||
|
|
|
|
Line 87: Line 87:
|
|
|-
|-
|Microglandular adenosis||Disease||
|[[BRST5:Microglandular adenosis|Microglandular adenosis]]||Disease||
|
|
|
|
Line 96: Line 96:
|
|
|-
|-
|Radial scar/complex sclerosing lesion||Disease||
|[[BRST5:Radial scar / complex sclerosing lesion|Radial scar/complex sclerosing lesion]]||Disease||
|
|
|
|
Line 105: Line 105:
|
|
|-
|-
|Tubular adenoma||Disease||
|[[BRST5:Tubular adenoma|Tubular adenoma]]||Disease||
|
|
|
|
Line 114: Line 114:
|
|
|-
|-
|Lactating adenoma||Disease||
|[[BRST5:Lactating adenoma|Lactating adenoma]]||Disease||
|
|
|
|
Line 134: Line 134:
!'''Notes'''
!'''Notes'''
|-
|-
|Ductal adenoma||Disease||
|[[BRST5:Ductal adenoma|Ductal adenoma]]||Disease||
|
|
|
|
Line 143: Line 143:
|
|
|-
|-
|Pleomorphic adenoma||Disease||
|[[BRST5:Pleomorphic adenoma|Pleomorphic adenoma]]||Disease||
|
|
|
|
Line 152: Line 152:
|
|
|-
|-
|Adenomyoepithelioma||Disease||
|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]||Disease||
|
|
|
|
Line 161: Line 161:
|
|
|-
|-
|Malignant adenomyoepithelioma||Disease||
|[[BRST5:Malignant adenomyoepithelioma|Malignant adenomyoepithelioma]]||Disease||
|
|
|
|
Line 170: Line 170:
|
|
|-
|-
|Intraductal papilloma||Disease||
|[[BRST5:Intraductal papilloma|Intraductal papilloma]]||Disease||
|
|
|
|
Line 179: Line 179:
|
|
|-
|-
|Papillary ductal carcinoma in situ||Disease||
|[[BRST5:Papillary ductal carcinoma in situ|Papillary ductal carcinoma in situ]]||Disease||
|
|
|
|
Line 188: Line 188:
|
|
|-
|-
|Encapsulated papillary carcinoma||Disease||
|[[BRST5:Encapsulated papillary carcinoma|Encapsulated papillary carcinoma]]||Disease||
|
|
|
|
Line 197: Line 197:
|
|
|-
|-
|Solid papillary carcinoma (in situ and invasive)||Disease||
|[[BRST5:Solid papillary carcinoma (in situ and invasive)|Solid papillary carcinoma (in situ and invasive)]]||Disease||
|
|
|
|
Line 206: Line 206:
|
|
|-
|-
|Invasive papillary carcinoma||Disease||
|[[BRST5:Invasive papillary carcinoma|Invasive papillary carcinoma]]||Disease||
|
|
|
|
Line 215: Line 215:
|
|
|-
|-
|Atypical lobular hyperplasia||Disease||
|[[BRST5:Atypical lobular hyperplasia|Atypical lobular hyperplasia]]||Disease||
|
|
|
|
Line 235: Line 235:
!'''Notes'''
!'''Notes'''
|-
|-
|Lobular carcinoma in situ||Disease||
|[[BRST5:Lobular carcinoma in situ|Lobular carcinoma in situ]]||Disease||
|
|
|
|
Line 244: Line 244:
|
|
|-
|-
|Ductal carcinoma in situ||Disease||
|[[BRST5:Ductal carcinoma in situ|Ductal carcinoma in situ]]||Disease||
|
|
|
|
Line 253: Line 253:
|
|
|-
|-
|Invasive breast carcinoma of no special type||Disease||
|[[BRST5:Invasive breast carcinoma of no special type|Invasive breast carcinoma of no special type]]||Disease||
|
|
|
|
Line 262: Line 262:
|
|
|-
|-
|Microinvasive carcinoma||Disease||
|[[BRST5:Microinvasive carcinoma|Microinvasive carcinoma]]||Disease||
|
|
|
|
Line 271: Line 271:
|
|
|-
|-
|Invasive lobular carcinoma||Disease||
|[[BRST5:Invasive lobular carcinoma|Invasive lobular carcinoma]]||Disease||
|
|
|
|
Line 280: Line 280:
|
|
|-
|-
|Tubular carcinoma||Disease||
|[[BRST5:Tubular carcinoma|Tubular carcinoma]]||Disease||
|
|
|
|
Line 289: Line 289:
|
|
|-
|-
|Cribriform carcinoma||Disease||
|[[BRST5:Cribriform carcinoma|Cribriform carcinoma]]||Disease||
|
|
|
|
Line 298: Line 298:
|
|
|-
|-
|Mucinous carcinoma||Disease||
|[[BRST5:Mucinous carcinoma|Mucinous carcinoma]]||Disease||
|
|
|
|
Line 307: Line 307:
|
|
|-
|-
|Mucinous cystadenocarcinoma||Disease||
|[[BRST5:Mucinous cystadenocarcinoma|Mucinous cystadenocarcinoma]]||Disease||
|
|
|
|
Line 316: Line 316:
|
|
|-
|-
|Invasive micropapillary carcinoma||Disease||
|[[BRST5:Invasive micropapillary carcinoma|Invasive micropapillary carcinoma]]||Disease||
|
|
|
|
Line 336: Line 336:
!'''Notes'''
!'''Notes'''
|-
|-
|Carcinoma with apocrine differentiation||Disease||
|[[BRST5:Carcinoma with apocrine differentiation|Carcinoma with apocrine differentiation]]||Disease||
|
|
|
|
Line 345: Line 345:
|
|
|-
|-
|Metaplastic carcinoma||Disease||
|[[BRST5:Metaplastic carcinoma|Metaplastic carcinoma]]||Disease||
|
|
|
|
Line 354: Line 354:
|
|
|-
|-
|[[BRST5:Acinic cell carcinoma|Acinic cell carcinoma]]||Disease||Patricija Zot
|[[BRST5:Acinic cell carcinoma|Acinic cell carcinoma]]||Disease||
|2/28/2024
|
|
|
|
|
|PENDING
|
|
|Katherine Geiersbach
|
|
|
|
Line 368: Line 368:
|COMPLETE
|COMPLETE
|
|
|Hui Chen / Katherine Geiersbach
|Katherine Geiersbach
|12/6/2023
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Morteza Seifi
|[[BRST5:Secretory carcinoma|Secretory carcinoma]]||Disease||Hui Chen / Katherine Geiersbach
|10/12/2022
|10/12/2022
|11/11/2023
|11/11/2023
Line 378: Line 378:
|
|
|Katherine Geiersbach
|Katherine Geiersbach
|
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|Mucoepidermoid carcinoma||Disease||
|[[BRST5:Mucoepidermoid carcinoma|Mucoepidermoid carcinoma]]||Disease||
|
|
|
|
Line 390: Line 390:
|
|
|-
|-
|Polymorphous adenocarcinoma||Disease||
|[[BRST5:Polymorphous adenocarcinoma|Polymorphous adenocarcinoma]]||Disease||
|
|
|
|
Line 405: Line 405:
|
|
|Katherine Geiersbach
|Katherine Geiersbach
|
|4/16/2025
|2021 template added
|2024 template added
|-
|-
|Neuroendocrine tumour||Disease||
|[[BRST5:Neuroendocrine tumour|Neuroendocrine tumour]]||Disease||
|
|
|
|
Line 417: Line 417:
|
|
|-
|-
|Neuroendocrine carcinoma||Disease||
|[[BRST5:Neuroendocrine carcinoma|Neuroendocrine carcinoma]]||Disease||
|
|
|
|
Line 458: Line 458:
----
----
|-
|-
|Hamartoma||Disease||
|[[BRST5:Hamartoma|Hamartoma]]||Disease||
|
|
|
|
Line 467: Line 467:
|
|
|-
|-
|[[BRST5:Fibroadenoma|Fibroadenoma]]||Disease||H. Evin Gulbahce / Patricija Zot
|[[BRST5:Fibroadenoma|Fibroadenoma]]|| ||
|8/11/2023
|
|11/11/2023
|
|PENDING
|
|
|
|
|
|
|
|
|2021 template added
|-
|-
|[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
|[[BRST5:Phyllodes tumour|Phyllodes tumour]]||Disease||Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach
Line 482: Line 482:
|
|
|
|
|
|1/8/2025
|2021 template added
|2024 template added
|-
|-
|
|
Line 506: Line 506:
----
----
|-
|-
|Syringomatous tumour||Disease||
|[[BRST5:Syringomatous tumour|Syringomatous tumour]]||Disease||
|
|
|
|
Line 515: Line 515:
|
|
|-
|-
|Nipple adenoma||Disease||
|[[BRST5:Nipple adenoma|Nipple adenoma]]||Disease||
|
|
|
|
Line 524: Line 524:
|
|
|-
|-
|Paget disease of the breast||Disease||
|[[BRST5:Paget disease of the breast|Paget disease of the breast]]||Disease||
|
|
|
|
Line 554: Line 554:
----
----
|-
|-
|Haemangioma||Disease||
|[[BRST5:Haemangioma|Haemangioma]]||Disease||
|
|
|
|
Line 574: Line 574:
!'''Notes'''
!'''Notes'''
|-
|-
|Angiomatosis||Disease||
|[[BRST5:Angiomatosis|Angiomatosis]]||Disease||
|
|
|
|
Line 583: Line 583:
|
|
|-
|-
|Atypical vascular lesions||Disease||
|[[BRST5:Atypical vascular lesions|Atypical vascular lesions]]||Disease||
|
|
|
|
Line 592: Line 592:
|
|
|-
|-
|Postradiation angiosarcoma of the breast||Disease||
|[[BRST5:Postradiation angiosarcoma of the breast|Postradiation angiosarcoma of the breast]]||Disease||
|
|
|
|
Line 601: Line 601:
|
|
|-
|-
|Primary angiosarcoma of the breast||Disease||
|[[BRST5:Primary angiosarcoma of the breast|Primary angiosarcoma of the breast]]||Disease||
|
|
|
|
Line 610: Line 610:
|
|
|-
|-
|Nodular fasciitis||Disease||
|[[BRST5:Nodular fasciitis|Nodular fasciitis]]||Disease||
|
|
|
|
Line 619: Line 619:
|
|
|-
|-
|Myofibroblastoma||Disease||
|[[BRST5:Myofibroblastoma|Myofibroblastoma]]||Disease||
|
|
|
|
Line 628: Line 628:
|
|
|-
|-
|Desmoid fibromatosis||Disease||
|[[BRST5:Desmoid fibromatosis|Desmoid fibromatosis]]||Disease||
|
|
|
|
Line 637: Line 637:
|
|
|-
|-
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Yajuan Liu
|[[BRST5:Inflammatory myofibroblastic tumour|Inflammatory myofibroblastic tumour]]||Disease||Katherine Geiersbach
|8/11/2023
|8/11/2023
|11/11/2023
|11/11/2023
Line 643: Line 643:
|
|
|Katherine Geiersbach
|Katherine Geiersbach
|12/27/2024
|1/8/2025
|2024 template  
|2024 template
|-
|-
|Schwannoma||Disease||
|[[BRST5:Schwannoma|Schwannoma]]||Disease||
|
|
|
|
Line 655: Line 655:
|
|
|-
|-
|Neurofibroma||Disease||
|[[BRST5:Neurofibroma|Neurofibroma]]||Disease||
|
|
|
|
Line 675: Line 675:
!'''Notes'''
!'''Notes'''
|-
|-
|Granular cell tumour||Disease||
|[[BRST5:Granular cell tumour|Granular cell tumour]]||Disease||
|
|
|
|
Line 684: Line 684:
|
|
|-
|-
|Leiomyoma||Disease||
|[[BRST5:Leiomyoma|Leiomyoma]]||Disease||
|
|
|
|
Line 693: Line 693:
|
|
|-
|-
|Leiomyosarcoma||Disease||
|[[BRST5:Leiomyosarcoma|Leiomyosarcoma]]||Disease||
|
|
|
|
Line 702: Line 702:
|
|
|-
|-
|Lipoma||Disease||
|[[BRST5:Lipoma|Lipoma]]||Disease||
|
|
|
|
Line 711: Line 711:
|
|
|-
|-
|Angiolipoma||Disease||
|[[BRST5:Angiolipoma|Angiolipoma]]||Disease||
|
|
|
|
Line 720: Line 720:
|
|
|-
|-
|Liposarcoma||Disease||
|[[BRST5:Liposarcoma|Liposarcoma]]||Disease||
|
|
|
|
Line 729: Line 729:
|
|
|-
|-
|Pseudoangiomatous stromal hyperplasia||Disease||
|[[BRST5:Pseudoangiomatous stromal hyperplasia|Pseudoangiomatous stromal hyperplasia]]||Disease||
|
|
|
|
Line 759: Line 759:
----
----
|-
|-
|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)||Disease||
|[[BRST5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]||Disease||
|
|
|
|
Line 768: Line 768:
|
|
|-
|-
|Follicular lymphoma||Disease||
|[[BRST5:Follicular lymphoma|Follicular lymphoma]]||Disease||
|
|
|
|
Line 788: Line 788:
!'''Notes'''
!'''Notes'''
|-
|-
|Diffuse large B-cell lymphoma||Disease||
|[[BRST5:Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma]]||Disease||
|
|
|
|
Line 797: Line 797:
|
|
|-
|-
|Burkitt lymphoma||Disease||
|[[BRST5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
|
|
|
|
Line 806: Line 806:
|
|
|-
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease||
|[[BRST5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||
|
|
|
|
Line 836: Line 836:
----
----
|-
|-
|Gynaecomastia||Disease||
|[[BRST5:Gynaecomastia|Gynaecomastia]]||Disease||
|
|
|
|
Line 845: Line 845:
|
|
|-
|-
|Carcinoma in situ||Disease||
|[[BRST5:Carcinoma in situ|Carcinoma in situ]]||Disease||
|
|
|
|
Line 854: Line 854:
|
|
|-
|-
|Invasive carcinoma||Disease||
|[[BRST5:Invasive carcinoma|Invasive carcinoma]]||Disease||
|
|
|
|
Line 863: Line 863:
|
|
|-
|-
|Metastases to the breast||Disease||
|[[BRST5:Metastases to the breast|Metastases to the breast]]||Disease||
|
|
|
|
Line 913: Line 913:
!'''Notes'''
!'''Notes'''
|-
|-
|[[BRST5:Cowden syndrome|Cowden syndrome]]||Disease||[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]]
|[[BRST5:Cowden syndrome|Cowden syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship statu]]<nowiki/>s [see [[GTS5:PTEN hamartoma tumour syndrome (PTEN)|PTEN hamartoma tumour syndrome (PTEN)]]]
|N/A
|N/A
|N/A
|N/A
Retrieved from "https://test.ccga.io/index.php/BRST5:Volunteer_Assignments_and_Opportunities"